{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:42:55Z","timestamp":1760366575500,"version":"build-2065373602"},"reference-count":50,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Aarhus University Department of Clinical Medicine, Health Research Foundation of Central Denmark Region, the Br\u00f8drene Hartmanns Foundation, the Carl and Ellen Hertz Foundation, the Danish Lymphoma Group, Kong Christian den Tiendes Foundation","award":["is not applicable for these grants"],"award-info":[{"award-number":["is not applicable for these grants"]}]},{"name":"The Torben and Alice Frimodts Foundation, the Aase and Ejnar Danielsens Foundation, the Foundation of 1870, the Einar Willumsens Foundation, the Dagmar Marshalls Foundation, the Fr\u00e6nkel Foundation, and the Karen Elise Jensen Foundation.","award":["is not applicable for these grants"],"award-info":[{"award-number":["is not applicable for these grants"]}]},{"name":"The mass spectrometry platform was kindly donated by A. P. M\u00f8ller og Hustru Chastine Mc-Kinney M\u00f8llers Fond til almene Formaal.","award":["is not applicable for these grants"],"award-info":[{"award-number":["is not applicable for these grants"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>In classic Hodgkin lymphoma (cHL), the tumour microenvironment (TME) is of major pathological relevance. The paucity of neoplastic cells makes it important to study the entire TME when searching for prognostic biomarkers. Cure rates in cHL have improved markedly over the last several decades, but patients with primary refractory disease still show inferior survival. We performed a proteomic comparison of pretreatment tumour tissue from ABVD treatment-refractory versus ABVD treatment-sensitive cHL patients, in order to identify biological differences correlating with treatment outcome. Formalin-fixed paraffin-embedded tumour tissues from 36 patients with cHL, 15 with treatment-refractory disease, and 21 with treatment-sensitive disease, were processed for proteomic investigation. Label-free quantification nano liquid chromatography tandem mass spectrometry was performed on the tissues. A total of 3920 proteins were detected and quantified between the refractory and sensitive groups. This comparison revealed several subtle but significant differences in protein expression which could identify subcluster characteristics of the refractory group. Bioinformatic analysis of the biological differences indicated that a number of pathologically activated signal transduction pathways are disturbed in ABVD treatment-refractory cHL.<\/jats:p>","DOI":"10.3390\/cancers14010247","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T20:42:16Z","timestamp":1641415336000},"page":"247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Classic Hodgkin Lymphoma Refractory for ABVD Treatment Is Characterized by Pathologically Activated Signal Transduction Pathways as Revealed by Proteomic Profiling"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3459-7429","authenticated-orcid":false,"given":"Bent","family":"Honor\u00e9","sequence":"first","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-4273","authenticated-orcid":false,"given":"Maja Dam","family":"Andersen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diani","family":"Wilken","sequence":"additional","affiliation":[{"name":"Department of Biomedicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Kamper","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"d\u2019Amore","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"},{"name":"Department of Pathology, Aarhus University Hospital, 8200 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5089-3271","authenticated-orcid":false,"given":"Maja","family":"Ludvigsen","sequence":"additional","affiliation":[{"name":"Department of Haematology, Aarhus University Hospital, 8200 Aarhus, Denmark"},{"name":"Department of Clinical Medicine, Aarhus University, 8000 Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised, IARC Press. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical Hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e462","DOI":"10.1016\/S2352-3026(18)30140-6","article-title":"Intensive treatment strategies in advanced-stage Hodgkin\u2019s lymphoma (HD9 and HD12): Analysis of long-term survival in two randomised trials","volume":"5","author":"Kreissl","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin\u2019s Disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V96.4.1280","article-title":"Prognostic factors and treatment outcome in primary pro-gressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group","volume":"96","author":"Josting","year":"2000","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900110404","article-title":"Infiltration of eosinophils in Hodgkin\u2019s disease involved lymph nodes predicts prog-nosis","volume":"11","author":"Enblad","year":"1993","journal-title":"Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/ejh.12747","article-title":"The role of tumour-infiltrating eosinophils, mast cells and macrophages in Classical and Nodular Lymphocyte Predominant Hodgkin Lymphoma in children","volume":"97","author":"Englund","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2001.02977.x","article-title":"Mast cells ex-press functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin\u2019s disease","volume":"114","author":"Molin","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ejh.12583","article-title":"Tumour-associated mast cells in classical Hodgkin\u2019s lymphoma: Correlation with histological subtype, other tumour-infiltrating inflammatory cell subsets and outcome","volume":"96","author":"Andersen","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-Associated Macrophages and Survival in Classic Hodgkin\u2019s Lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3324\/haematol.2010.031542","article-title":"Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin\u2019s lymphoma","volume":"96","author":"Kamper","year":"2010","journal-title":"Haematologica"},{"key":"ref_13","first-page":"248","article-title":"The classical Hodgkin\u2019 s lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J. Patol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1182\/blood-2007-09-112128","article-title":"Proteomics analysis of Hodgkin lymphoma: Identification of new players involved in the cross-talk between HRS cells and infiltrating lymphocytes","volume":"111","author":"Ma","year":"2008","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/labinvest.3700672","article-title":"Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed\u2013Sternberg cells by LC-MS\/MS","volume":"87","author":"Wallentine","year":"2007","journal-title":"Lab. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.1182\/blood-2010-12-327346","article-title":"Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed\/refractory disease in classical Hodgkin lymphoma","volume":"117","author":"Kamper","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemi-ology: The Danish National Pathology Registry and Data Bank","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2147\/CLEP.S99470","article-title":"Danish National Lymphoma Registry","volume":"8","author":"Arboe","year":"2016","journal-title":"Clin. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Arboe, B., El-Galaly, T.C., Clausen, M.R., Munksgaard, P.S., Stoltenberg, D., Nygaard, M.K., Klausen, T.W., Christensen, J.H., G\u00f8rl\u00f8v, J.S., and Brown, P.D.N. (2016). The Danish National Lymphoma Registry: Coverage and Data Quality. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157999"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/978-1-0716-0255-3_3","article-title":"Proteomic Protocols for Differential Protein Expression Analyses","volume":"2110","year":"2020","journal-title":"Methods Mol Biol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ludvigsen, M., Thorlacius-Ussing, L., Vorum, H., Moyer, M.P., Stender, M.T., Thorlacius-Ussing, O., and Honor\u00e9, B. (2020). Proteomic charac-terization of colorectal cancer cells versus normal-derived colon mucosa cells: Approaching identification of novel diagnos-tic protein biomarkers in colorectal cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21103466"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat. Protoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","article-title":"The Perseus computational platform for comprehensive analysis of (prote)omics data","volume":"13","author":"Tyanova","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","article-title":"Causal analysis approaches in Ingenuity Pathway Analysis","volume":"30","author":"Green","year":"2014","journal-title":"Bioinformatics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","article-title":"Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia","volume":"10","author":"Kashyap","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"117534","DOI":"10.1016\/j.lfs.2020.117534","article-title":"CXCL12\/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis","volume":"249","author":"Mortezaee","year":"2020","journal-title":"Life Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejca.2012.05.005","article-title":"A review on CXCR4\/CXCL12 axis in oncology: No place to hide","volume":"49","author":"Kruizinga","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/path.1725","article-title":"Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin\u2019s lymphoma cells through a mechanism involving Akt kinase and mTOR","volume":"205","author":"Dutton","year":"2005","journal-title":"J. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1038\/sj.bjc.6605968","article-title":"CXCL12\u2013CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: A novel target for therapy","volume":"103","author":"Singh","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1593\/neo.12324","article-title":"CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy","volume":"14","author":"Nagengast","year":"2012","journal-title":"Neoplasia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"105092","DOI":"10.1016\/j.phrs.2020.105092","article-title":"Relevance of the CXCR4\/CXCR7-CXCL12 axis and its effect in pathophysiological conditions","volume":"161","author":"Huynh","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.canlet.2012.08.012","article-title":"Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options","volume":"328","author":"Audrito","year":"2013","journal-title":"Cancer Lett."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Peng, S.B., Zhang, X., Paul, D., Kays, L.M., Ye, M., Vaillancourt, P., Dowless, M., Stancato, L.F., Stewart, J., and Uhlik, M.T. (2016). Inhibition of CXCR4 by LY2624587, a fully humanized anti-CXCR4 antibody induces apoptosis of hemato-logic malignancies. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150585"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1152\/physrev.00003.2005","article-title":"Mammalian G Proteins and Their Cell Type Specific Functions","volume":"85","author":"Wettschureck","year":"2005","journal-title":"Physiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrm2299","article-title":"Heterotrimeric G protein activation by G-protein-coupled receptors","volume":"9","author":"Oldham","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3389\/fphar.2019.00339","article-title":"The endocannabinoid system as a target in cancer diseases: Are we there yet?","volume":"10","author":"Moreno","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1111\/bph.14331","article-title":"Insights into the effects of the endocannabinoid system in cancer: A review","volume":"175","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10555-012-9352-1","article-title":"The Eph\/Ephrin family in cancer metastasis: Communication at the service of invasion","volume":"31","author":"Kandouz","year":"2012","journal-title":"Cancer Metastasis Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nrc1188","article-title":"Cannabinoids: Potential anticancer agents","volume":"3","year":"2003","journal-title":"Nat. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"31","DOI":"10.18632\/oncoscience.289","article-title":"The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma","volume":"3","author":"Zhang","year":"2016","journal-title":"Oncoscience"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Benz, A.H., Renn\u00e9, C., Maronde, E., Koch, M., Grabiec, U., Kallendrusch, S., Rengstl, B., Newrzela, S., Hartmann, S., and Hansmann, M.-L. (2013). Expression and Functional Relevance of Cannabinoid Receptor 1 in Hodgkin Lymphoma. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081675"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrm.2015.16","article-title":"Mechanisms of ephrin-Eph signalling in development, physiology and disease","volume":"17","author":"Kania","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cytogfr.2004.09.002","article-title":"The role of ephrins and Eph receptors in cancer","volume":"15","author":"Surawska","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1038\/s41388-019-0931-2","article-title":"Eph receptor signalling: From catalytic to non-catalytic functions","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: Bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2013.590","article-title":"EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties","volume":"34","author":"Miao","year":"2014","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejmech.2017.07.029","article-title":"Targeting Eph\/ephrin system in cancer therapy","volume":"142","author":"Lodola","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2016.09.012","article-title":"KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study","volume":"50","author":"Swords","year":"2016","journal-title":"Leuk. Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:00:20Z","timestamp":1760364020000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/1\/247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["cancers14010247"],"URL":"https:\/\/doi.org\/10.3390\/cancers14010247","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2022,1,4]]}}}